{"doc_id": "33301246", "type of study": "Therapy", "title": "", "abstract": "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.\nSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic.\nSafe and effective vaccines are needed urgently.\nIn an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 \u03bcg per dose).\nBNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein.\nThe primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety.\nA total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo.\nThere were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6).\nSimilar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions.\nAmong 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient.\nThe safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache.\nThe incidence of serious adverse events was low and was similar in the vaccine and placebo groups.\nA two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older.\nSafety over a median of 2 months was similar to that of other viral vaccines.\n(Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).\nCopyright \u00a9 2020 Massachusetts Medical Society.\n", "Evidence Map": {"Enrollment": [{"term": "laboratory-confirmed Covid-19", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 89}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "BNT162b2 mRNA Covid-19 Vaccine", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 57, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 39, "end": 46, "has_count": ["2019"]}], "has_procedure": [{"text": "bnt162b2 mrna coronavirus", "maps_to": "C5401375:Coronavirus", "start": 0, "end": 25}], "has_relation": "N/A"}], "Outcome": [{"term": "Safety", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}, {"term": "Efficacy", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 19}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) infection and the resulting coronavirus disease 2019 ( Covid-19 ) have afflicted tens of millions of people in a worldwide pandemic .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Safe and effective vaccines are needed urgently .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "In an ongoing multinational , placebo-controlled , observer-blinded , pivotal efficacy trial , we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses , 21 days apart , of either placebo or the BNT162b2 vaccine candidate ( 30 \u03bcg per dose ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 37, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "BNT162b2", "negation": "affirmed", "UMLS": {}, "start": 228, "end": 236, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "BNT162b2 is a lipid nanoparticle-formulated , nucleoside-modified RNA vaccine that encodes a prefusion stabilized , membrane-anchored SARS-CoV-2 full-length spike protein .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety .", "Evidence Elements": {"Participant": [{"term": "laboratory-confirmed Covid-19", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 89}], "Intervention": [{"term": "vaccine", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 51, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 36}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 94, "end": 100}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "A total of 43,548 participants underwent randomization , of whom 43,448 received injections : 21,720 with BNT162b2 and 21,728 with placebo .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "BNT162b2", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 114, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo ; BNT162b2 was 95 % effective in preventing Covid-19 ( 95 % credible interval , 90.3 to 97.6 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "BNT162b2", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 127, "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 166, "end": 173, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "BNT162b2", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 127, "has_relation": "N/A"}], "Outcome": [{"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 30}, {"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 30}], "Observation": [{"term": "95 % effective", "negation": "affirmed", "UMLS": {}, "start": 189, "end": 203}], "Count": [{"term": "8 cases", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 18}, {"term": "162 cases", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 141}]}, "Evidence Propositions": [{"Intervention": {"term": "BNT162b2", "has_relation": "N/A"}, "Observation": "95 % effective", "Outcome": "Covid-19", "Count": ""}, {"Intervention": {"term": "BNT162b2", "has_relation": "N/A"}, "Observation": "", "Count": "8 cases", "Outcome": "Covid-19"}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "", "Count": "162 cases", "Outcome": "Covid-19"}]}, {"Section": "RESULTS", "Text": "Similar vaccine efficacy ( generally 90 to 100 % ) was observed across subgroups defined by age , sex , race , ethnicity , baseline body-mass index , and the presence of coexisting conditions .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "vaccine efficacy", "negation": "affirmed", "UMLS": {}, "start": 8, "end": 24}], "Observation": [{"term": "generally", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 36}, {"term": "90 to 100 %", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 48}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Among 10 cases of severe Covid-19 with onset after the first dose , 9 occurred in placebo recipients and 1 in a BNT162b2 recipient .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 89, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "BNT162b2", "negation": "affirmed", "UMLS": {}, "start": 112, "end": 120, "has_relation": "N/A"}], "Outcome": [{"term": "severe Covid-19", "negation": "affirmed", "UMLS": {}, "start": 18, "end": 33}], "Observation": [], "Count": [{"term": "10 cases", "negation": "affirmed", "UMLS": {}, "start": 6, "end": 14}, {"term": "9", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 33}, {"term": "1", "negation": "affirmed", "UMLS": {}, "start": 6, "end": 7}]}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The safety profile of BNT162b2 was characterized by short-term , mild-to-moderate pain at the injection site , fatigue , and headache .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "BNT162b2", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 30, "has_relation": "N/A"}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 10}, {"term": "fatigue", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 118}], "Observation": [{"term": "short-term , mild-to-moderate pain at the injection site", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 108}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "BNT162b2", "has_relation": "N/A"}, "Observation": "short-term , mild-to-moderate pain at the injection site", "Outcome": "fatigue", "Count": ""}]}, {"Section": "RESULTS", "Text": "The incidence of serious adverse events was low and was similar in the vaccine and placebo groups .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "vaccine", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 78, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 90, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "incidence of serious adverse events", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 39}], "Observation": [{"term": "low", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 47}, {"term": "similar", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 63}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "vaccine", "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "low", "Outcome": "incidence of serious adverse events", "Count": ""}, {"Intervention": [{"term": "vaccine", "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Observation": "similar", "Outcome": "incidence of serious adverse events", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "A two-dose regimen of BNT162b2 conferred 95 % protection against Covid-19 in persons 16 years of age or older .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "two-dose regimen of BNT162b2", "negation": "affirmed", "UMLS": {}, "start": 2, "end": 30, "has_relation": "N/A"}], "Outcome": [{"term": "Covid-19", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 73}], "Observation": [{"term": "95 % protection", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 56}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "two-dose regimen of BNT162b2", "has_relation": "N/A"}, "Observation": "95 % protection", "Outcome": "Covid-19", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "Safety over a median of 2 months was similar to that of other viral vaccines .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "other viral vaccines", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 76, "has_chemical": [{"text": "other viral vaccines", "maps_to": "C3653947:Other viral vaccines", "start": 0, "end": 20}], "has_relation": "N/A"}], "Outcome": [{"term": "Safety", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}], "Observation": [{"term": "similar", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 44}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "other viral vaccines", "has_chemical": [{"text": "other viral vaccines", "maps_to": "C3653947:Other viral vaccines", "start": 0, "end": 20}], "has_relation": "N/A"}], "Observation": "similar", "Outcome": "Safety", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "( Funded by BioNTech and Pfizer ; ClinicalTrials.gov number , NCT04368728 . ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Massachusetts Medical Society .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}